Riskpilot← Back to searchSign inGet full accessBioextrax AB (publ)
ABActiveOrg 5569651473Skiffervägen 76Research and experimental development on natural sciences and engineering · NACE 7210Est. 201410-19 employees
Revenue 2024
SEK 515K
-75% vs 2023
EBITDA margin
-3180.6%
+21% vs 2023
Equity ratio
89.9%
Financial strength
Net profit 2024
SEK -17,3M
+19% vs 2023
| Revenue | SEK 515K | -75% |
| EBITDA | SEK -16,4M | +21% |
| Net profit | SEK -17,3M | +19% |
| Total assets | SEK 29M | +29% |
| Equity | SEK 26,1M | +27% |
| Employees | — | — |
Legal name
Bioextrax AB (publ)
Org number
5569651473
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 mars 2014
Share capital
SEK 1 969 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva forskning, utveckling och marknadsföring av material och metodik baserade på en bioteknologisk utvinningsteknologi och därmed förenlig verksamhet.
Address
Skiffervägen 76
Email
edh@bioextrax.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 10 | 0 | 0 | 22 | 276 | 395 | 2 056 | 515 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 63 | −102 | 67 | −852 | −1 875 | −5 397 | −10 179 | −18 190 | −20 738 | −16 380 |
| Depreciation & amort. | −0 | −0 | −9 | −33 | −113 | −172 | −350 | −477 | −861 | −1 159 |
| EBIT | 63 | −102 | 58 | −885 | −1 988 | −5 569 | −10 529 | −18 667 | −21 599 | −17 539 |
| Net financials | — | — | — | −2 | −1 | −3 | −3 | — | 92 | 201 |
| Profit before tax | 62 | −102 | 57 | −887 | −1 989 | −5 572 | −10 532 | −18 667 | −21 507 | −17 338 |
| Tax | −8 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 54 | −102 | 57 | −887 | −1 989 | −5 572 | −10 532 | −18 667 | −21 507 | −17 338 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 242 | 110 | 468 | 1 719 | 1 738 | 3 034 | 12 641 | 37 917 | 22 515 | 28 996 |
| Equity | 180 | 78 | 191 | 295 | 1 232 | 1 654 | 7 499 | 31 767 | 20 536 | 26 059 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 62 | 32 | 276 | 1 424 | 506 | 1 380 | 5 142 | 6 150 | 1 979 | 2 937 |
| Total debt | 62 | 32 | 276 | 1 424 | 506 | 1 380 | 5 142 | 6 150 | 1 979 | 2 937 |
EBITDA margin
-3180.6%
This company
15.8%
Market median
-20230% vs market
20152024
Equity ratio
89.9%
This company
38.2%
Market median
+135% vs market
20152024
Return on equity
-66.5%
This company
18.4%
Market median
-461% vs market
20152024
Net profit margin
-3366.6%
This company
8.1%
Market median
-41663% vs market
20152024
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20152024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PM Chief Auditor | Chief Auditor | 2020 | — | — |
HO Chief Auditor | Chief Auditor | 2022 | — | — |
CE Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2021 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2024 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bioextrax AB (publ) also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Martin Henriksson | Chief Auditor | 0 companies |
| Henry Oskar Stefan Svensson | Chief Auditor | 0 companies |
| Carl Edvard Georg Hall | Chief Executive Officer | 0 companies |
| Richard Norton Börje Tooby | Board of Directors | 0 companies |
| Kjell Fredrik Sjödin | Board of Directors | 0 companies |
| Claes Håkan Björnberg | Board of Directors | 0 companies |
| Leif Robert Nilsson | Board of Directors | 0 companies |
| Mohammad Hamed Ahmad Ibrahim | Board of Directors | 0 companies |
| Robert Per Hökfelt | Chairman | 0 companies |
| Mats Olle Persson | Chairman | 0 companies |
| Rajni Hatti Kaul | Chairman | 0 companies |
| Klaudija Pavlic Cavala | Board of Directors | 0 companies |
| Marie Grönborg | Board of Directors | 0 companies |